Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00569244 |
The investigational drug SH T00186D is an oral contraceptive. The investigational drug used in this study contains the estrogen ethinylestradiol (EE) and the progestogen drospirenone (DRSP).
The aim of the present study is to evaluate efficacy and safety of the investigational drug in the treatment of menstrual pain (pelvic pain occurring shortly before, at onset, during menstruation). Two different regimens of intake of the same investigational product will be compared.
Patients have to undergo 2 -3 Baseline cycles (depending on whether the patient was an OC user before), during which menstrual pain, bleeding events, and pain killer intake have to be documented. During this observation period, the intake of hormonal contraceptives is not allowed. Other contraceptive methods (condoms with spermicide, pessary with spermicide) have to be used. If the patient is eligible for the study, she will be randomly assigned to one of the two treatment groups. Treatment group A will take the medication according to an extended flexible regimen, i.e., tablet intake will be triggered by bleeding events. Treatment group B will take the study medication in the 24 + 4 days regimen. That means, tablets to be taken on cycle days
1 - 24 contain the hormone combination, whereas tablets 25 - 28 do not contain any active ingredients, i.e., these are so called placebo tablets.
Treatment will last at least 140 days, but can be prolonged in Treatment Group A depending of occurrence of menstrual bleeding. The overall study duration will be 10 months for each patient. During the whole study period, 5 visits are planned. At Screening and Final examination, a thorough physical examination and a gynecological examination (including breath palpation and cervical smear ) will be performed. Blood samples will be taken for safety laboratory parameters.
Additional examinations can be performed any time, if this becomes necessary for medical reasons.
Patients will be provided with a patient diary to document the intake of study medication, any bleeding events and days without bleeding, pregnancy test results, any dysmenorrheic (menstrual) pain and its intensity and its interference with daily activity, and intake of pain medication. The pain medication (ibuprofen) will be provided.
Condition | Intervention | Phase |
---|---|---|
Primary Dysmenorrhea |
Drug: YAZ flex (SH T00186D) Drug: YAZ (SH T00186D) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Open-Label, Randomized, Controlled, Parallel-Group Study to Assess Efficacy and Safety of an Extended Flexible Regimen of the Combined Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Beta-Cyclodextrin Clathrate and 3 mg Drospirenone) Compared to the Conventional Regimen of SH T00186D in the Treatment of Primary Dysmenorrhea |
Enrollment: | 218 |
Study Start Date: | December 2007 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Drug: YAZ flex (SH T00186D)
Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
|
Arm 2: Active Comparator |
Drug: YAZ (SH T00186D)
YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
|
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Age between 18 and 40 years (inclusive) with smoking habits as follows:
Exclusion Criteria:
Germany | |
Berlin, Germany, 13086 | |
Berlin, Germany, 12587 | |
Berlin, Germany, 10247 | |
Berlin, Germany, 10409 | |
Germany, Baden-Württemberg | |
Heidelberg, Baden-Württemberg, Germany, 69112 | |
Germany, Bayern | |
Nürnberg, Bayern, Germany, 90491 | |
Germany, Hessen | |
Frankfurt, Hessen, Germany, 60439 | |
Fulda, Hessen, Germany, 36037 | |
Mühlheim, Hessen, Germany, 63165 | |
Germany, Niedersachsen | |
Hannover, Niedersachsen, Germany, 30459 | |
Hannover, Niedersachsen, Germany, 30159 | |
Germany, Sachsen | |
Wurzen, Sachsen, Germany, 04808 | |
Leipzig, Sachsen, Germany, 04277 | |
Leipzig, Sachsen, Germany, 04299 | |
Leipzig, Sachsen, Germany, 04207 | |
Leipzig, Sachsen, Germany, 04207 | |
Germany, Sachsen-Anhalt | |
Magdeburg, Sachsen-Anhalt, Germany, 39126 | |
Magdeburg, Sachsen-Anhalt, Germany, 39104 | |
Jessen, Sachsen-Anhalt, Germany, 06917 | |
Bernburg, Sachsen-Anhalt, Germany, 06406 | |
Burg, Sachsen-Anhalt, Germany, 39288 | |
Magdeburg, Sachsen-Anhalt, Germany, 39130 | |
Blankenburg, Sachsen-Anhalt, Germany, 38889 | |
Germany, Thüringen | |
Kahla, Thüringen, Germany, 07768 | |
Gera, Thüringen, Germany, 07545 | |
United Kingdom | |
London, United Kingdom, W12 0HS | |
United Kingdom, Derbyshire | |
Chesterfield, Derbyshire, United Kingdom, S40 4TF | |
United Kingdom, Tyne and Wear | |
Newcastle Upon Tyne, Tyne and Wear, United Kingdom, NE4 5BE |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Schering Pharma AG ( Therapeutic Area Head ) |
Study ID Numbers: | 91587, EudraCT No.: 2006-004899-13, 310882 |
Study First Received: | December 5, 2007 |
Last Updated: | March 16, 2009 |
ClinicalTrials.gov Identifier: | NCT00569244 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Primary Dysmenorrhea Menstrual Pain Oral Contraception |
Contraceptives, Oral, Combined Signs and Symptoms Pelvic Pain Menstruation Disturbances Dysmenorrhea Contraceptive Agents |
Contraceptives, Oral Contraceptive Agents, Female Drospirenone Ethinyl Estradiol Pain |
Contraceptive Agents Contraceptives, Oral Physiological Effects of Drugs Contraceptive Agents, Female Pain Reproductive Control Agents Pharmacologic Actions |
Contraceptives, Oral, Combined Signs and Symptoms Pathologic Processes Pelvic Pain Dysmenorrhea Menstruation Disturbances Therapeutic Uses |